中信证券指出，当前政策红利、数据资产与商业健康险产品迭代形成共振，有望开启医疗健康产业多元 化支付体系发展新周期。国金证券表示，创新药企正逐步迎来扭亏节点，行业高质量发展转型期的结构 性机会值得关注，具备全球研发实力与稳健现金流的龙头企业有望持续受益。 以上信息仅供参考，不构成投资建议 2月27日，截至13：20，恒生生物科技指数上涨1.99%。个股方面，药明合联涨超8%，云顶新耀涨超 5%，药明生物等涨超4%。同花顺数据显示，恒生生物科技ETF易方达（159105）盘中换手率达到 90%，交投活跃！ 消息面上，2 月 26 日，康希诺生物披露 2025 年度业绩快报，全年营业总收入 10.68 亿元，同比增长 26.18%，归母净利润 2787.27 万元，同比增长 107.36%，实现扭亏为盈；同日，百济神州发布 2025 年 度业绩快报，归母净利润 14.22 亿元，同比成功扭亏，为港股生物板块注入信心。2 月 25 日，天辰生物 医药向港交所主板递交上市申请，公司专注于过敏性及自身免疫性疾病生物药物的自主研发，进一步丰 富港股生物赛道优质供给；同日，康方生物自主研发的 1 类新药曼多奇单抗注射液上市申 ...

Market Overview - A-shares showed mixed performance with the Shanghai Composite Index down 0.01%, Shenzhen Component Index up 0.19%, and ChiNext Index down 0.29% as of market close [1] - Total trading volume in Shanghai, Shenzhen, and Beijing reached 25,568 billion, an increase of 756 billion from the previous day [1] ETF Performance - The China-Korea Semiconductor ETF surged by 9.64%, leading the market, driven by the recovery in the semiconductor supply chain [2] - The National 2000 ETF rose by 5.04%, indicating a rebound in small-cap growth stocks [2] - The Electric Grid sector performed well, with the Electric Grid ETF up 3.23% and the Electric Grid Equipment ETFs rising by 3.22% and 2.91% respectively [2] Communication Sector - The communication sector also saw gains, with ETFs in this category rising between 2.73% and 2.78% [3] Declining Sectors - The pharmaceutical sector faced a broad retreat, with the Hang Seng Biotechnology ETF showing the largest decline at -3.89% [4] - Other related ETFs in the healthcare and biotechnology sectors also experienced significant drops, indicating a market shift from defensive sectors to technology growth [4] Trading Activity - The Short-term Bond ETF had a trading volume exceeding 66 billion, leading in activity among ETFs [5] - The top traded ETFs included the Short-term Bond ETF at 661.12 billion and the Silver Day Benefit ETF at 167.16 billion [5] Turnover Rates - Cross-border products showed high trading activity, with the Brazil ETF and China-Korea Semiconductor ETF having turnover rates of 171.99% and 125.76% respectively [6][7] - The National Debt ETF also maintained a strong turnover rate of 88.09%, indicating active trading in interest rate bonds and cross-border assets [7] New ETF Launch - A new Technology Growth ETF by Industrial Bank is set to launch on February 27, with a focus on hard technology and a multi-factor strategy targeting the top 50 securities in various tech sectors [8]

Market Performance - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) experienced a strong rebound today, rising by 3.3% with a trading volume increasing to 500 million [1] Core Drivers - Liquidity expectations have improved as the U.S. December non-farm payroll data fell short of expectations, leading to heightened market anticipation for a Federal Reserve interest rate cut, with the CME "FedWatch" indicating a 40.7% probability of a rate cut in March [2] Industry Updates - Research and Development Progress: Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved for market launch as the first domestic drug of its kind [2] - Business Development Activity: GSK has entered into a collaboration with AstraZeneca worth over $2 billion, setting a record for domestic clinical-stage small molecule anti-cancer drug collaborations. The total transaction amount for outbound licensing in 2025 is projected to reach $135.655 billion [2]